Biotech founded by ex-Novo reseacher raises capital for new oral obesity treatment
The biotech company, Pila Pharma, is raising 20 million Swedish kronor in an almost fully covered capital raise, which includes a stock option for future use. The goal is to expand the clinical pipeline with a separate dedicated obesity track and thereby explore more applications for the company's oral TRPV1 inhibitor for obesity and type 2 diabetes, a potential first-in-class candidate.
